高凝状态肿瘤患者抗凝联合化疗的临床观察  

Clinical Observation of Anticoagulation Combined Chemotherapy in the Treatment of Malignant Tumor Patients with Hypercoagulable State

作　　者：曲爱忠[1] 于秀丽[1] 付永兴[1] 

机构地区：[1]潍坊市益都中心医院,山东青州262500

出　　处：《医学与哲学（B）》2013年第7期54-56,共3页Medicine & Philosophy(B)

摘　　要：观察伴高凝状态恶性肿瘤患者抗凝联合化疗的临床疗效。观察组68例,给予一线标准方案化疗,同时给予低分子肝素钙6 000U,1次/d,皮下注射,阿司匹林100mg口服,1次/d,21d为1个周期,共2个周期。对照组56例,给予一线标准方案化疗。结果显示,治疗组和对照组有效率分别为23.69%和19.44%,两组比较,差异无统计学意义(P>0.05);治疗组和对照组生存状态评分(KPS)改善率分别为64.71%和35.39%,两组比较,差异有统计学意义(P<0.05)。治疗组出现了纤维蛋白原(Fbg)、组织因子(TF)和D-二聚体(D-D)含量的降低,与对照组相比差异有统计学意义(P<0.01)。从而得出伴高凝状态恶性肿瘤患者进行抗凝联合化疗,临床疗效较好,同时可以降低血液高凝状态和血栓形成的风险。To observe the clinical effect of anticoagulation combined chemotherapy in the treatment of malignant tumor pa- tients with hypercoagulable state. 68 patients were selected, they were accepted the treatment of the first standard chemo- therapy and anticoagulation. The treatment of anticoagulation included low--molecular--weight heparin calcium 6 000 U ih and asprin 100 mg po, qd, the treatment was repeated every 21 days. After 2 cycles of chemotherapy, the efficacy was e- valuated. The other 56 patients of the control group were only accepted the first standard chemotherapy. The efficacious rates were 23.69% （treatment group） and 19.44% （control group）, there was no significant difference （P〉0.05）. The KPS improvement rate of the two groups were 64.71% and 35.39%, there was a significant difference （P〈0. 05）. The content of Fbg,TF,and D--D degraded in the treatment group, there was significant difference in the two groups（P〈0.01）. It is benefit from anticoagulation combined chemotherapy for the malignant tumor patients with hypereoagulable state, at the same time, the risk of thrombogenesis and hypercoagulabale state degrades.

关 键 词：恶性肿瘤 高凝状态 抗凝 化疗 

分 类 号：R730.53[医药卫生—肿瘤]